Respiratory diseases are one of the leading causes of death worldwide. The World Health Organization (WHO) estimates that by 2030, respiratory diseases will be the cause of one in five deaths worldwide. Over the years, available technologies such as pulmonary function tests and blood bioassays have played an important role in the diagnosis and monitoring of lung diseases. Diagnostic assessment of severe breathing of stenosis based on Sang -based markers, such as CRP -protein (CRP), PHPPTIDE (BNB) obtained from the brain, tropen and cases of iritinophyll. These biological markers are mainly used for single pathological patients, but have poor discrimination in patients with a sharp respiratory path. Blood biomaterials can be less far from target organs (in cardiovascular and cardiovascular lungs, there is an unnecessary need for the development of important and specific biomarkers that distinguish it with strong breathing stenosis and attached. Cardiovascular conditions are difficult.